TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15930042
Drug: TNF-alpha 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF-alpha 0.5 mg
Study: 15930042
Drug: TNF-alpha 1
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF-alpha 1 mg
Study: 15930042
Drug: TNF-alpha 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF-alpha 2 mg
Study: 15930042
Drug: TNF-alpha 3/4
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF-alpha 3/4 mg
Study: 15930042
Drug: All TNF-alpha
Normalized name: all-rac-alpha-tocopherol
DrugBank: DL-alpha-Tocopherol (DB14476)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All TNF-alpha doses
Study: 15930042
Drug: Higher TNF-alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher TNF-alpha doses
Study: 12027069
Drug: Biminne capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biminne capsules (5 capsules twice a day for 12 weeks)
Study: 12027069
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 capsules twice a day for 12 weeks)
Study: 12027069
Drug: Biminne (dose-response
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biminne (dose-response study)
Study: 12027069
Drug: Biminne treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biminne treatment
Study: 9500317
Drug: Low-dose cyclosporin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporin (trough blood concentrations of 75-125 ng/mL)
Study: 9500317
Drug: Normal-dose cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-dose cyclosporin (trough blood concentrations of 150-250 ng/mL)
Study: 9500317
Drug: Normal-dose cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-dose cyclosporin
Study: 21989185
Drug: 4 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cycles of anthracycline chemotherapy
Study: 17287823
Drug: NBI‐34041 (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBI‐34041 (10, 50, or 100 mg)
Study: 7944433
Drug: Portal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Portal infusion chemotherapy (n=5)
Study: 7944433
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy (n=6)
Study: 7944433
Drug: Arterial infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arterial infusion chemotherapy (n=8)
Study: 3984837
Drug: Cibenzoline (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cibenzoline (1.0 mg/kg IV, then 1 mg/kg increments to a maximum of 3.0 mg/kg)
Study: 3984837
Drug: Procainamide (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procainamide (1000 mg IV, then 1500 mg)
Study: 3984837
Drug: Chronic oral
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic oral cibenzoline therapy (mean follow-up of 8.8 months)
Study: 15037402
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (80 mg daily)
Study: 30477827
Drug: 700 mg
Normalized name: cystine 700 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700 mg Zataria multiflora Boiss. (Shirazi thyme) powder twice daily for 12 weeks
Study: 27538497
Drug: DA9301 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA9301 (1000 mg/day for 4 weeks)
Study: 25306810
Drug: Conventional circumcision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional circumcision (CC), n = 120
Study: 19819914
Drug: 3-weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-weekly docetaxel (group D)
Study: 19819914
Drug: 3-weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-weekly docetaxel alternating with 3-weekly gemcitabine (group D/G)
Study: 15077032
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide inhalation (20 ppm administered 10 min after reperfusion)
Study: 15077032
Drug: Placebo gas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gas (administered 10 min after reperfusion)
Study: 10680840
Drug: VEGF plasmid/liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF plasmid/liposome (P/L) gene transfer (1000 microg of VEGF)
Study: 10680840
Drug: beta-galactosidase plasmid/liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-galactosidase plasmid/liposome (P/L) gene transfer (1000 microg of beta-galactosidase)
Study: 8245283
Drug: Pill placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill placebo plus clinical management
Study: 30415650
Drug: Eperisone hydrochloride
Normalized name: Eperisone hydrochloride
DrugBank: Eperisone (DB08992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eperisone hydrochloride 50 mg (sugar-coated tablet)
Study: 30415650
Drug: Eperisone hydrochloride
Normalized name: Eperisone hydrochloride
DrugBank: Eperisone (DB08992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eperisone hydrochloride 50 mg (film-coated tablet)
Study: 30415650
Drug: Eperisone hydrochloride
Normalized name: Eperisone hydrochloride
DrugBank: Eperisone (DB08992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eperisone hydrochloride 50 mg (both formulations)
Study: 19247757
Drug: Intranasal 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal 5% lidocaine plus naphazoline solution 0.2 mg ml(‐1)
Study: 19247757
Drug: Topical intranasal
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical intranasal saline 20 ml (control group)
Study: 10768245
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g i.v. 30 min preinterventionally
Study: 10768245
Drug: No study
Approvals — FDA: no, EMA: no, PMDA: no
Description: No study medication (control group)
Study: 9357093
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (500 mg sodium valproate) under fasting conditions (treatment A)
Study: 9357093
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (500 mg sodium valproate) after ingestion of 14 g citrus pectin (treatment B)
Study: 3081599
Drug: Cromolyn (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromolyn (12 doses of 20 mg)
Study: 3081599
Drug: Cromolyn (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromolyn (single dose)
Study: 20496791
Drug: Sporobakterin liquid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sporobakterin liquid, a suspension for oral use
Study: 16098081
Drug: Peginterferon alpha-2a
Normalized name: PEGINTERFERON ALPHA-2A 180MCG/ML INJ,1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon alpha-2a 180 mg/week with ribavirin for 48 weeks
Study: 16098081
Drug: Peginterferon alpha-2a
Normalized name: PEGINTERFERON ALPHA-2A 180MCG/ML INJ,1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon alpha-2a 180 mg/week without ribavirin for 48 weeks
Study: 16098081
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (peginterferon/ribavirin)
Study: 10099040
Drug: Ceftibuten alone
Normalized name: Ceftibuten
DrugBank: Ceftibuten (DB01415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftibuten alone (400 mg)
Study: 10099040
Drug: Ceftibuten with
Normalized name: Ceftibuten
DrugBank: Ceftibuten (DB01415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftibuten with antacid (Mylanta Double-Strength Liquid; 60 mL)
Study: 10099040
Drug: Ceftibuten with
Normalized name: Ceftibuten
DrugBank: Ceftibuten (DB01415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftibuten with ranitidine (150 mg/12 hours after 3 days of dosing)
Study: 20924607
Drug: IVIG 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 0.5 g/kg at 12 h postnatal age
Study: 20924607
Drug: IVIG 1
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 1 g/kg at 12 h postnatal age
Study: 20924607
Drug: IVIG group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG group (both doses)
Study: 19170847
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone patch (TTP)
Study: 16689842
Drug: No beta-blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No beta-blocker therapy (MI patients)
Study: 11251672
Drug: Intensive education
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive education on lifestyle (diet, exercise, smoking) with polypharmacological treatment
Study: 9924378
Drug: Control (anti-inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (anti-inflammatory drugs only)
Study: 7816294
Drug: Emla cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emla cream applied for at least 2 hours prior to injection
Study: 3140155
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium 4% ophthalmic solution (Opticrom)
Study: 3140155
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching drug vehicle)
Study: 30540619
Drug: Task-oriented EMG-triggered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Task-oriented EMG-triggered electrical stimulation therapy for wrist/finger extensors in addition to conventional physical therapy for 5 sessions a week for 4 weeks.
Study: 30540619
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy for 20 sessions.
Study: 30540619
Drug: Task-oriented EMG-triggered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Task-oriented EMG-triggered electrical stimulation therapy.
Study: 27131100
Drug: Electrolyte maintenance
Normalized name: Truelyte Advanced Hydration Electrolyte Maintenance Solution (Fruit Punch)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrolyte maintenance solution (n=324)
Study: 24456217
Drug: rosuvastatin 5
Normalized name: rosuvastatin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 5 mg/day or 10 mg/day
Study: 16192591
Drug: Doxorubicin 50
Normalized name: DOXOrubicin 50 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 50 mg/m² and Docetaxel 75 mg/m² (AT)
Study: 16192591
Drug: Fluorouracil 500
Normalized name: fluorouracil 500 MG in 10 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil 500 mg/m², Doxorubicin 50 mg/m², and Cyclophosphamide 500 mg/m² (FAC)
Study: 12047485
Drug: Dextromethorphan (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (0.7 mg kg(‐1))
Study: 12047485
Drug: Ketamine (0.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.375 mg kg(‐1))
Study: 10091823
Drug: Amiodarone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (300 mg intravenously over 1 h, followed by 20 mg/kg over the next 24 h plus 600 mg orally, in three doses, for 1 week, then 400 mg/day orally, for three weeks)
Study: 10091823
Drug: Propafenone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (2 mg/kg intravenously over 15 min, followed by 10 mg/kg over 24 h and then 450 mg/day orally, for one month)
Study: 8543508
Drug: Therapy for
Normalized name: nutritional therapy for GSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy for sexually abused children
Study: 8543508
Drug: Future sexual
Normalized name: Zinc Gluconate 50 mg ORAL CAPSULE [Pegasus Male Sexual Enhancer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Future sexual abuse therapy outcome research considerations
Study: 2407764
Drug: Ornithine alpha-ketoglutarate
Normalized name: ornithine alpha-ketoglutarate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornithine alpha-ketoglutarate (OKG) 10 g (3.6 g alpha KG and 6.4 g ORN)
Study: 2407764
Drug: Ornithine hydrochloride
Normalized name: Ornithine hydrochloride
DrugBank: Ornithine (DB00129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornithine hydrochloride 6.4 g
Study: 2407764
Drug: Calcium alpha-ketoglutarate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium alpha-ketoglutarate 3.6 g
Study: 373415
Drug: L-Histidine, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Histidine, 4 g/day
Study: 7109499
Drug: VAC/FMC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC/FMC plus 5 mg/m2 Corynebacterium parvum (CP) subcutaneously on day 1
Study: 30917820
Drug: Group (G)
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group (G)
Study: 21822934
Drug: Intravenous 10%
Normalized name: fat emulsion, intravenous 10% intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 10% caprylate-chromatography purified immunoglobulin
Study: 19348602
Drug: Bromfenac sodium
Normalized name: Bromfenac Sodium
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromfenac sodium (BF) 0.1% ophthalmic solution with disodium cromoglycate (DSCG) 2.0%
Study: 19348602
Drug: Fluorometholone (FML)
Normalized name: Fluorometholone
DrugBank: Fluorometholone (DB00324)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluorometholone (FML) 0.02% ophthalmic suspension with disodium cromoglycate (DSCG) 2.0%
Study: 19348602
Drug: Patient preference
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient preference for concomitant treatment
Study: 17472472
Drug: Seaweed (Alaria
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seaweed (Alaria esculenta), 5 g/day for 7 weeks
Study: 17472472
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein isolate, 141.3 mg of isoflavones/day for the last week of each treatment arm
Study: 17472472
Drug: Placebo, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 5 g/day for 7 weeks
Study: 11981081
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (6 g/day)
Study: 7726397
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 6 mg.kg‐1.h‐1
Study: 7726397
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 12 mg.kg‐1.h‐1
Study: 2074175
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for restoration of venous patency and valvular function
Study: 2074175
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment with heparin, oral anticoagulants, and compression stockings
Study: 2074175
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for ilio-femoral DVT
Study: 2074175
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment for ilio-femoral DVT
Study: 20842109
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg, vitamin C 1 g, and vitamin E 1,000 IU
Study: 15565596
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus preoperative treatment with recombinant human IL‐2 (34 patients)
Study: 12445025
Drug: rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 mg orally each morning (07.00 h)
Study: 12445025
Drug: rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 mg orally each evening (18.00 h)
Study: 10662482
Drug: Coformulation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coformulation of low dose aspirin plus modified-release dipyridamole
Study: 2304776
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A treatment for 4 months
Study: 2304776
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A treatment
Study: 6775296
Drug: isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: isosorbide dinitrate (ID) 5 mg
Study: 6775296
Drug: nitroglycerin microcapsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: nitroglycerin microcapsules (NGMC) 7.5 mg
Study: 6775296
Drug: pentaerythritol tetranitrate
Normalized name: Pentaerythritol tetranitrate
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pentaerythritol tetranitrate (PETN) 160 mg
Study: 30496299
Drug: HIV‐DNA intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV‐DNA intradermal priming regimens (Group I: 2x0.1mL [3mg/mL], Group II: 2x0.1mL [3mg/mL] plus electroporation, Group III: 1x0.1mL [6mg/mL] plus electroporation)
Study: 30496299
Drug: HIV‐MVA administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV‐MVA administered with or without CN54rgp140/GLA‐AF
Study: 26399404
Drug: Bedtime ingestion
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime ingestion of hypertension medications
Study: 26399404
Drug: Morning ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning ingestion of hypertension medications
Study: 24788781
Drug: Monthly household
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly household food basket (FB) plus nutrition education (NE)
Study: 30509271
Drug: Metformin (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2000 mg daily)
Study: 20196651
Drug: History of
Normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: History of TB treatment
Study: 19137863
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia (tetracaine 0.5% eye drops and preservative free lidocaine 2% intracamerally)
Study: 19137863
Drug: Retrobulbar anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrobulbar anesthesia (4 mL lidocaine 2% into the retrobulbar space)
Study: 15771597
Drug: Prostaglandin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin therapy
Study: 10760336
Drug: Customary diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Customary diet with placebo pill for 2 menstrual cycles
Study: 8558188
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 800 mg/d orally
Study: 27638452
Drug: Telemedicine intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemedicine intervention (not specified dosage or duration)
Study: 24841866
Drug: Family Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family Behavior Therapy (FBT)
Study: 17617527
Drug: Weekly intravenous
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly intravenous cisplatin at 40 mg/m2 for 6 weeks in combination with radiation therapy (RT)
Study: 16228060
Drug: Ketoconazole (KCZ)
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole (KCZ) administered during the stimulation phase to 28 patients.
Study: 24511648
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with baseline eGFR < 60 ml/min (Intervention vs Control)
Study: 24511648
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with baseline eGFR >= 60 ml/min (Intervention vs Control)
Study: 21700760
Drug: Multimodal nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal nutritional rehabilitation (health education, oral nutritional supplements, exercise, oral testosterone) for 90 days
Study: 18347680
Drug: Quercetin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (1000 mg daily for 6 weeks)
Study: 18347680
Drug: Placebo (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1000 mg daily for 6 weeks)
Study: 14653888
Drug: Cetrorelix (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrorelix (3 mg single dose)
Study: 3174724
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g fructose-1,6-diphosphate (FDP)
Study: 6122939
Drug: 7.5 g
Normalized name: glucose 15 GM per 37.5 GM Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 g dextrose
Study: 29904824
Drug: Monthly minodronate
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly minodronate 50 mg every 4 weeks
Study: 29904824
Drug: Weekly alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly alendronate or risedronate
Study: 26779704
Drug: Training program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training program 'Active and safe with wheeled walkers' for 10 weeks (90 min, twice a week)
Study: 1105502
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg of salmefamol given by metered aerosol
Study: 8153718
Drug: Subcutaneous adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous adrenaline
Study: 1105502
Drug: Subcutaneous atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous atropine
Study: 31826336
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (540,000 IU single enteral dose)
Study: 27790824
Drug: G‐CSF combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF combined with intramyocardial (i.m.) injection of autologous bone marrow-derived cells (BMCs)